GlassScriptPhysician profile
Jill Buckthal-Mccuin
NPI 1780803098
$10,641.31
in general payments reported to CMS, 2019-2025
24 companies · $2,592 in 2025
The $2,592 reported for 2025 was more than what 90% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $72.30 · 2021: $310 · 2022: $1,596 · 2023: $2,705 · 2024: $3,214 · 2025: $2,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,503 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,502.73 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,716.34 | 2022-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $1,158.14 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $725.26 | 2021-2025 | |
| Pfizer INC. | $707.82 | 2022-2025 | |
| Janssen Biotech, INC. | $690.55 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $671.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $617.14 | 2020-2025 | Dupixent, Libtayo |
| Amgen INC. | $581.39 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $580.42 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $519.86 | 2020-2025 | Winlevi, Ilumya |
| Incyte Corporation | $428.61 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $360.87 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $351.75 | 2021-2025 | Nemluvio, Aklief, Dysport |
| E.R. Squibb & Sons, L.L.C. | $293.48 | 2022-2025 | Sotyktu |
| Ucb, INC. | $274.13 | 2024-2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $269.97 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $254.84 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.88 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Almirall LLC | $97.30 | 2022-2025 | Seysara |
| Biofrontera INC. | $59.43 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.68 | 2023-2025 | Spevigo |
| Boston Scientific Corporation | $30.37 | 2024 | |
| Tempus Ai, INC | $24.97 | 2024 | Merlin Test |
| Verrica Pharmaceuticals INC. | $21.59 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Buckthal-Mccuin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.